Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...

Investing.com — Foghorn Therapeutics Inc . (NASDAQ: FHTX )，一家市值为2.3135亿美元的制药公司，宣布修改其与TD Securities (USA) LLC的普通股销售协议，有效降低了其场内交易 (ATM)发行的潜在股票销售规模。今天进行的这项修订将可用股份从2亿美元缩减至1亿美元。

Vicki DeArmon launched Foghorn Press and Sibylline Press, and has now written an “almost true” memoir of San Francisco’s ...

Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Free Report) have earned a consensus rating of “Buy” from the six ...

Local and visiting writers offering new novels and non-fiction titles ranging from reportage to business to memoir (and more!

As the founder of a small publishing company in 1980s San Francisco, Vicki DeArmon recruited authors, negotiated contracts and persuaded stores to stock her books. Almost always, she said recently, ...

A look at how Newcastle Music Festival has launched careers and helped to define our city's cultural identity.

Foghorn Therapeutics Inc. announced continued enrollment in its Phase 1 trial for FHD-909, a first-in-class oral selective SMARCA2 inhibitor targeting SMARCA4 mutated cancers, particularly non ...

March 06, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting ...

It's been 10 years since Shawn Sherlock opened the doors to FogHorn, Newcastle's first contemporary craft brewhouse, and he's ...

A malfunctioning foghorn has been blaring every 30 seconds off the coast of a Narragansett, Rhode Island, beach for the last few weeks. Narragansett residents spoke to NBC 10 about the relentless ...